Hybrid simultaneous whole-body 2-[
Humans
Fluorodeoxyglucose F18
Multiple Myeloma
/ diagnosis
Smoldering Multiple Myeloma
Prospective Studies
Positron-Emission Tomography
Magnetic Resonance Imaging
/ methods
Whole Body Imaging
/ methods
Bone Diseases
Radiopharmaceuticals
/ pharmacology
Positron Emission Tomography Computed Tomography
/ methods
Clinical decision-making
Diagnostic techniques, radioisotope
Magnetic resonance imaging
Multiple myeloma
Positron emission tomography
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
07
09
2022
accepted:
22
02
2023
revised:
10
01
2023
medline:
11
8
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
Mixing diagnostic and prognostic data provided by whole-body MRI (WB-MRI) and 2- All patients with confirmed NDMM at the Nantes University Hospital were prospectively enrolled in this study and underwent WB-2-[ A total of 52 patients were included in this study. PET and MRI were equally effective at detecting patients with FL (69% vs. 75%) and with diffuse BMI (62% for both) in the symptomatic MM group. WB-2-[ WB-2-[ • Whole-body 2-[
Identifiants
pubmed: 37022439
doi: 10.1007/s00330-023-09593-1
pii: 10.1007/s00330-023-09593-1
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6438-6447Informations de copyright
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Références
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Hillengass J, Usmani S, Rajkumar SV et al (2019) International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302–e312
doi: 10.1016/S1470-2045(19)30309-2
pubmed: 31162104
Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9):1606–10
doi: 10.1200/JCO.2009.25.5356
pubmed: 20177023
Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA (2014) The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 28(12):2402–2403
doi: 10.1038/leu.2014.230
pubmed: 25079172
Zamagni E, Nanni C, Gay F et al (2016) 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30(2):417–422
doi: 10.1038/leu.2015.291
pubmed: 26490489
Moreau P, Attal M, Caillot D et al (2017) Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol 35(25):2911–2918
Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23):5989–5995
doi: 10.1182/blood-2011-06-361386
pubmed: 21900189
Bartel TB, Haessler J, Brown TLY et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114(10):2068–2076
doi: 10.1182/blood-2009-03-213280
pubmed: 19443657
pmcid: 2744568
Abe Y, Ikeda S, Kitadate A et al (2019) Low hexokinase-2 expression-associated false-negative (18) F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 46(6):1345–1350
doi: 10.1007/s00259-019-04312-9
pubmed: 30903198
Jamet B, Morvan L, Nanni C et al (2021) Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging 48(4):1005–1015
doi: 10.1007/s00259-020-05049-6
pubmed: 33006656
Benaniba L, Tessoulin B, Trudel S et al (2019) The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 19(1):855
doi: 10.1186/s12885-019-6080-8
pubmed: 31464608
pmcid: 6714387
Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology 291(1):5–13
doi: 10.1148/radiol.2019181949
pubmed: 30806604
Dutoit J, Vanderkerken M, Verstraete KL (2013) Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. Eur J Radiol 82(9):1444–1452
doi: 10.1016/j.ejrad.2013.04.012
pubmed: 23726124
Nanni C, Zamagni E, Versari A et al (2016) Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 43(3):414–421
doi: 10.1007/s00259-015-3200-9
pubmed: 26475305
Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21(8):1713–1718
doi: 10.1007/s00330-011-2116-4
pubmed: 21472473
Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
doi: 10.4065/78.1.21
pubmed: 12528874
Westerland O, Amlani A, Kelly-Morland C et al (2021) Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 48(8):2558–2565
doi: 10.1007/s00259-020-05182-2
pubmed: 33469686
pmcid: 8241666
Burns R, Mulé S, Blanc-Durand P et al (2021) Optimization of whole-body 2-[
Rasche L, Angtuaco E, McDonald JE et al (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130(1):304
doi: 10.1182/blood-2017-03-774422
Aljama MA, Sidiqi MH, Buadi FK et al (2018) Utility and prognostic value of 18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol 93(12):1518–1523
doi: 10.1002/ajh.25279
pubmed: 30194770
Jung S-H, Kwon SY, Min J-J et al (2019) 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system. Eur J Nucl Med Mol Imaging 46(1):107–115
doi: 10.1007/s00259-018-4114-0
pubmed: 30187105
Michaud-Robert AV, Zamagni E, Carlier T et al (2020) Glucose metabolism quantified by SUV
doi: 10.3390/cancers12092532
pubmed: 32899991
Cavo M, Terpos E, Nanni C et al (2017) International Myeloma Working Group. Review Role of
doi: 10.1016/S1470-2045(17)30189-4
pubmed: 28368259
Moulopoulos LA, Dimopoulos MA, Christoulas D et al (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 24:1206–1212
doi: 10.1038/leu.2010.70
pubmed: 20428203
Paschali A, Panagiotidis E, Triantafyllou T et al (2021) A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging 48(5):1487–1497
doi: 10.1007/s00259-020-05078-1
pubmed: 33099659